And AbbVie and Genmab scoop their ASH presentation with new data.
ApexOnco Front Page
Recent articles
The company adds royalty aggregation to its R&D business.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The disappointing Pynnacle trial is set to yield registrational data.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
